Table 3. Multivariable adjusted hazard ratios for prostate cancer recurrence and prostate cancer-specific mortality following radical prostatectomy by estrogen receptor subtype staining intensity.
| Recurrence Free Survival | Prostate Cancer-Specific Mortality$ | |||
|---|---|---|---|---|
|
|
||||
| *HR (95% CI) | p-value | *HR (95% CI) | p-value | |
| Nuclear ERβ2 | ||||
| No Staining | Referent | |||
| Weak Staining | 0.61 (0.07-5.16) | 0.65 | ||
| Intense Staining | 3.89 (1.12-13.42) | 0.03 | ||
|
| ||||
| Cytoplasmic ERβ1 | ||||
| No Staining | Referent | Referent | ||
| Weak Staining | 0.97 (0.53-1.80) | 0.93 | 1.11 (0.11-11.36) | 0.93 |
| Intense Staining | 1.72 (1.13-2.62) | 0.01 | 6.62 (1.75-24.95) | 0.01 |
*
All models adjusted for age, Gleason sum, pathologic stage and PSA at diagnosis; HR=hazard ratio, CI=confidence interval.
$
Values represent results from separate Cox proportional hazard models containing clinical factors* and the specified receptor.
Note: Nuclear ERβ2 staining was not significantly associated with recurrence free survival on co-variate analysis and as a result was not included in multivariable analysis.